A Moroccan Giant’s Playbook for Algerian Entrepreneurs
Morocco’s Laprophan is betting MAD 374 million ($35 million) on a cutting-edge sterile injectables plant near Rabat, part of a MAD 2.22 billion ($210 million) stock-market listing that will make it one of North Africa’s most formidable pharmaceutical players. The move isn’t just about scaling up production—it’s a blueprint for how Algerian entrepreneurs and the diaspora can seize opportunities in a region where healthcare demand is exploding, but local manufacturing remains underdeveloped.
The new EU-GMP-certified facility, set to open in 2027, will churn out 30 million injectable units annually—a volume that dwarfs Algeria’s current output. While Algeria’s SIDAL and Sotepharma dominate the domestic market, they face stiff competition from Morocco’s Amanys Pharma (acquired by Laprophan in March 2024), which already supplies GlaxoSmithKline and holds 350+ marketing authorizations for hospital and oncology drugs. Laprophan’s expansion is a wake-up call: Algeria risks falling behind in a sector where exports could fetch billions.
Why Algeria’s Pharma Sector Needs a Diaspora-Driven Revival
Algeria’s pharmaceutical industry is worth over $3 billion annually, with 80% of production consumed locally. Yet, the country imports critical injectables and biologics—areas where Laprophan is now positioning itself as a regional hub. For Algerian entrepreneurs, the gaps are clear:
– Regulatory hurdles: Algeria’s National Agency for Medicines and Health Products (ANMP) has tightened approvals, but Morocco’s faster clearance times (thanks to EU-GMP standards) attract foreign investors.
– Export potential: Laprophan’s listing will let it tap European and African markets—a niche Algeria’s SONATRACH-linked pharma firms have yet to exploit.
– Diaspora capital: Algerians in France, Canada, and the Gulf control $100+ billion in remittances annually. Many have pharma, biotech, or supply-chain expertise—but few channel it back into Algeria’s struggling industry.
Key example: The Algerian diaspora runs dozens of generic drug firms in France and Switzerland, yet only three (like Pharma5) have repatriated production. Laprophan’s move proves that scale and EU compliance are non-negotiable—Algeria’s entrepreneurs must either partner with Moroccan or Turkish firms or build their own GMP-certified plants.
How Algerian Startups Can Compete—and Win
Laprophan’s strategy hinges on three levers that Algerian founders can replicate:
1. Acquire, Don’t Just Build
2. Lock in Foreign Partners Early
3. Leverage Algeria’s Raw Materials
Case in point: Algerian olive oil is cheaper than Moroccan—yet no local firm exports it for pharma-grade use. A startup could process and sell it to European drugmakers for €5/kg vs. €8/kg from Tunisia.
The Diaspora’s Untapped Pharma Goldmine
Algerian expats in France (1.5 million), Canada (200,000), and the UAE (50,000) dominate pharma distribution, logistics, and R&D. Yet few invest in Algeria’s production base. Why?
– Fear of bureaucracy: ANMP approvals take 18-24 months—vs. 6-12 months in Morocco.
– Lack of local hubs: No Algerian pharma incubators like Morocco’s PharmaMed Hub.
– Tax uncertainty: Repatriated profits face corporate tax (25%) + VAT (19%)—higher than in Dubai (0%) or Portugal (12%).
Solution: The government should fast-track GMP certifications for diaspora-backed firms and offer tax holidays for first 3 years of production. Model: Tunisia’s API (Agence de Promotion de l’Industrie)—which slashed red tape for foreign investors.
The Race for African Markets—Algeria’s Missed Chance?
Laprophan’s listing isn’t just about Morocco—it’s about controlling Africa’s $40 billion pharma market. Algeria’s SONATRACH-linked firms have zero presence in Nigeria, Ivory Coast, or Senegal, where Moroccan and Indian generics dominate.
Missed opportunity: Algeria’s SIDAL exports $50 million/year—mostly to Saudi Arabia and Libya. Meanwhile, Morocco’s pharma exports hit $1.2 billion in 2025, with 30% going to Africa.
How to catch up:
– Partner with African distributors (e.g., Nigeria’s May & Baker).
– Offer “Algerian-made” branding—a selling point in Muslim-majority markets.
– Use Algeria’s gas advantage: SONATRACH could supply cheap energy to pharma plants (vs. Morocco’s electricity shortages).
Key takeaway for entrepreneurs
Algeria’s pharma sector is ripe for disruption—but success demands speed, EU standards, and diaspora partnerships. Entrepreneurs should target hospital drugs, leverage raw materials, and secure foreign contracts now before Morocco locks in Africa’s market. The window to compete is narrower than ever.
Sources
💡 Starting a business in Algeria? GlobalStart guides you step by step: procedures, real costs, company forms (SARL, EURL, SPA) and CNRC registration.